Explain this page
Arphra AIPlain-English read on Outlook Therapeutics, Inc.’s valuation06-16today
- OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review5d
- Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time5d
- Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD6d
- Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity16d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $1.00 (-45.35%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +15.80% | +15.08% | +490.42% | +421.13% | -0.56% | +15.80% | +8.91% | -94.71% | -96.09% | -99.69% | -99.73% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$1.83
308 sh
Bid
$1.82
1,400 sh
Ask
$1.83
220 sh
Spread
$0.010
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Real Estate+1.29%
- Industrials+0.60%
- Basic Materials+0.51%
- Energy+0.42%
- Healthcare-0.00%
- Utilities-0.10%
- Financial Services-0.24%
- Consumer Defensive-0.64%
- Consumer Cyclical-0.73%
- Communication Services-0.79%
- Technology-1.02%
Top industries (issuer's industry highlighted)
- Biotechnology+8.32%
- Financial - Mortgages-3.58%
- Electrical Equipment & Parts+2.87%
- Independent Power Producers+2.76%
- Staffing & Employment Services-2.76%
- Software - Infrastructure-2.69%
- Electronic Gaming & Multimedia-2.67%
- Hardware, Equipment & Parts+2.63%
- Apparel - Footwear & Accessories-2.52%
- REIT - Specialty+2.51%
- Engineering & Construction+2.14%
- Agricultural - Machinery+2.03%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Reviewzacks.com·Jun 17, 2026
- Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Timebenzinga.com·Jun 17, 2026
- Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMDglobenewswire.com·Jun 16, 2026
- Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunityseekingalpha.com·Jun 06, 2026
Peers
No peer list available for OTLK.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|